HR 2821: FDA Modernization Act 3.0

HR 2821 in plain English: This bill requires the FDA to update its regulations to formally replace references to animal testing with references to nonclinical testing throughout the rules governing investigational new drug applications. The FDA must publish this updated rule within one year of the bill becoming law, and the rule must take effect immediately as an interim final rule. It implements a provision from the Consolidated Appropriations Act of 2023 that already authorized alternatives to animal testing.

Stated purpose

This bill requires the FDA to update its regulations within one year to formally allow alternatives to animal testing — such as lab-based or computer models — when evaluating new drugs for investigational use, implementing a change Congress already authorized in 2023.

Key points

• Requires the FDA to replace 'animal testing' language with 'nonclinical testing' in drug application regulations.
• FDA must publish the updated rule within one year of enactment.
• The rule takes effect immediately upon publication as an interim final rule.
• Implements a 2023 law that authorized non-animal testing alternatives for new drug applications.

Arguments supporters make

• Congress already approved allowing alternatives to animal testing in 2023, and this bill simply forces the FDA to update its written rules to match — closing a gap between law and regulation.
• Modern non-animal testing methods like cell models and computer simulations can be faster and cheaper, potentially speeding up drug development and lowering costs.
• Reducing reliance on animal testing addresses ethical concerns shared across the political spectrum, and this bill has broad bipartisan support reflecting wide agreement on the goal.

Arguments opponents make

• Animal testing has decades of safety data behind it, and moving away from it before non-animal alternatives are fully validated could introduce unknown risks in drug safety reviews.
• Bypassing the normal rule-making process — by requiring the rule to take immediate effect without the usual public comment period — limits transparency and the ability of scientists or the public to flag problems before the rule is finalized.
• The bill mandates a one-year deadline for a sweeping regulatory overhaul across many sections of federal code, which may rush the FDA into changes without adequate time to ensure consistency and accuracy.

Tradeoffs

Speeding up the adoption of non-animal testing methods may advance both ethics and innovation, but doing so by skipping standard notice-and-comment rulemaking reduces public input and the ability to catch unintended consequences before the rules take effect.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week